VentureBeat

BiPar Sciences, maker of tumor-targeting cancer treatments, will be acquired by public global pharmaceutical company Sanofi-aventis. The two companies have signed a binding agreement that could deliver more than $500 million to BiPar, divided into varying milestone payments.

via VentureBeat.

Popularity: 18% [?]